Therefore, we initiated a real-world study to investigate the therapeutic responses and disease progression patterns in advanced NSCLC patients harboring EGFR exon 18 mutations who were treated with four diverse therapy strategies: 1G EGFR-TKI (gefitinib, erlotinib, or icotinib), the 2G EGFR-TKI afatinib, chemotherapy, and a 1G EGFR-TKI in combination with chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.